Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

Clinical Trial ID NCT04131218

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04131218

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017 3.90
2 Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010 2.32
3 Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 1.31
4 Sugammadex and ideal body weight in bariatric surgery. Anesthesiol Res Pract 2013 0.85
5 Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010 0.83
6 Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial. Anesthesiology 2017 0.75
Next 100